David Polsky, MD, PhD, Alfred W. Kopf, MD Professor of Dermatologic Oncology, Ronald O. Perelman Department of Dermatology, professor, Department of Pathology, and director, Pigmented Lesion Service, NYU Langone’s Perlmutter Cancer Center, discusses potential applications of circulating tumor DNA (ctDNA) as a biomarker in melanoma.
Video Reports
Dr. Long on Rationale for Nivolumab/Ipilimumab in Patients With Melanoma Who Have Brain Mets
Georgina V. Long, BSc, PhD, MBBS, FRACP, co-medical director of Melanoma Institute Australia (MIA), chair of Melanoma Medical Oncology and Translational Research at MIA and Royal North Shore Hospital, University of Sydney, discusses the rationale for the combination of nivolumab (Opdivo) and ipilimumab (Yervoy) in patients with melanoma who have brain metastases.
Timing of Immunotherapy Discontinuation Remains Challenging in Melanoma
Thomas Marron, MD, an assistant professor of medicine, hematology and medical oncology at Mount Sinai Hospital, discusses the rationale for investigating immunotherapy discontinuation in patients with melanoma.
Dr. Warner Discusses Findings from COMBI-i Trial in Melanoma
Allison Betof Warner, MD, PhD, assistant professor and assistant attending at Memorial Sloan Kettering Cancer Center, discusses the excitement surrounding the findings from the COMBI-i trial that was presented at the 2019 ASCO Annual Meeting.